Financial reports
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
6 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
1 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-K/A
2017 FY
Annual report (amended)
10 Aug 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K
2017 FY
Annual report
9 Mar 18
Current reports
8-K
Astellas Completes Acquisition of Audentes Therapeutics
15 Jan 20
8-K
Departure of Directors or Certain Officers
16 Dec 19
8-K
Astellas Enters into Definitive Agreement to
3 Dec 19
8-K
Results of Operations and Financial Condition
7 Nov 19
8-K
Other Events
8 Oct 19
8-K/A
Submission of Matters to a Vote of Security Holders
23 Aug 19
8-K
Results of Operations and Financial Condition
6 Aug 19
8-K
Departure of Directors or Certain Officers
28 Jun 19
8-K
Departure of Directors or Certain Officers
7 Jun 19
8-K
Departure of Directors or Certain Officers
29 May 19
Registration and prospectus
15-12B
Securities registration termination
27 Jan 20
POSASR
Automatic shelf registration (post-effective amendment)
15 Jan 20
POS AM
Prospectus update (post-effective amendment)
15 Jan 20
POS AM
Prospectus update (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
25-NSE
Exchange delisting
15 Jan 20
SC 14D9/A
Tender offer solicitation (amended)
15 Jan 20
Other
EFFECT
Notice of effectiveness
21 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
UPLOAD
Letter from SEC
11 Sep 18
CORRESP
Correspondence with SEC
10 Aug 18
UPLOAD
Letter from SEC
6 Aug 18
CT ORDER
Confidential treatment order
23 Apr 18
EFFECT
Notice of effectiveness
23 Aug 17
CORRESP
Correspondence with SEC
22 Aug 17
CT ORDER
Confidential treatment order
22 Aug 17
EFFECT
Notice of effectiveness
18 Apr 17
Ownership
3
Taysha Gene Therapies, Inc.
31 Oct 22
SC 13D
Taysha Gene Therapies, Inc.
31 Oct 22
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Audentes Therapeutics, Inc.
11 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
4
Thomas P Soloway
15 Jan 20
4
Julie Smith
15 Jan 20
4
Thomas J. Schuetz
15 Jan 20